PLASMA-LYTE 148 (pH 7.4)

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

MAGNESIUM CHLORIDE HEXAHYDRATE; POTASSIUM CHLORIDE; SODIUM ACETATE TRIHYDRATE; SODIUM CHLORIDE; SODIUM GLUCONATE

Disponible depuis:

TEVA ISRAEL LTD

Code ATC:

B05BB01

forme pharmaceutique:

SOLUTION FOR INFUSION

Composition:

SODIUM GLUCONATE 5.02 G/L; SODIUM ACETATE TRIHYDRATE 3.68 G/L; MAGNESIUM CHLORIDE HEXAHYDRATE 0.30 G/L; POTASSIUM CHLORIDE 0.37 G/L; SODIUM CHLORIDE 5.26 G/L

Mode d'administration:

I.V

Type d'ordonnance:

Required

Fabriqué par:

BAXTER HEALTHCARE LTD.UK

Domaine thérapeutique:

ELECTROLYTES

indications thérapeutiques:

Indicated as a source of water and electrolytes or as an alkalinizing agent.

Date de l'autorisation:

2020-01-27

Résumé des caractéristiques du produit

The format of this leaflet was determined by the Ministry of Health
and its content was
checked and approved in January 2020
1
NAME OF THE MEDICINAL PRODUCT
Plasma-Lyte
®
148 (pH 7.4)
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sodium Chloride:
..........................................................................................................
5.26 g/l
Potassium Chloride:
......................................................................................................
0.37 g/l
Magnesium Chloride hexahydrate:
...............................................................................
0.30 g/l
Sodium Acetate trihydrate:
...........................................................................................
3.68 g/l
Sodium Gluconate:
.......................................................................................................
5.02 g/l
Na
+
K+
Mg
++
Cl
-
CH
3
COO
-
(Acetate)
C
6
H
11
O
7
-
(Gluconate)
mmol/l
140
5.0
1.5
98
27
23
mEq/l
140
5.0
3.0
98
27
23
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Solution for intravenous (IV) infusion.
Clear solution, free from visible particles
Osmolarity: 295 mOsm/l (approx.)
pH: approx. 7.4 (6.5 to 8.0)
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Indicated as a source of water and electrolytes or as an alkalinizing
agent.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Plasma-Lyte
®
148 (pH 7.4) is compatible with blood or blood components. It may be
administered prior to or following the infusion of blood through the
same administration set
(i.e., as a priming solution), added to or infused concurrently with
blood components, or used
as a diluent in the transfusion of packed erythrocytes. Plasma-Lyte
®
148 (pH 7.4) and 0.9%
Sodium Chloride Injection, USP are equally compatible with blood or
blood components.
All injections in VIAFLEX plastic containers are intended for
intravenous administration using
sterile and nonpyrogenic equipment.
As directed by a physician. Dosage, rate and duration of
administration are to be i